Originally published by our sister publication Clinical Oncology News
By Kate O’Rourke
In patients with metastatic, castration-resistant prostate cancer (mCRPC), adding the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna, Pfizer) to the current standard-of-care enzalutamide (Xtandi, Astellas/Pfizer), an androgen receptor pathway inhibitor, significantly improved progression-free survival (PFS) compared with enzalutamide alone. This news, from the phase 3 TALAPRO-2 trial,